NCT06125522 - TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 10, 2024

Primary Completion Date

November 4, 2025

Study Completion Date

November 4, 2025

Conditions

Breast Cancer

Interventions

DRUG

vepdegestrant

Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days

DRUG

Samuraciclib

Daily oral dosages of Samuraciclib continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days

Trial Locations (21)

1070

Institut Jules Bordet, Anderlecht

20900

Fondazione IRCCS San Gerardo dei Tintori, Monza

21079

Centre Georges François Leclerc, Dijon

62269

Memorial Hospital East, Shiloh

Siteman Cancer Center - Shiloh, Shiloh

63031

Siteman Cancer Center - North County, Florissant

63110

Barnes-Jewish Hospital, St Louis

Washington University School of Medicine, St Louis

63129

Siteman Cancer Center - South County, St Louis

63141

Siteman Cancer Center - West County, Creve Coeur

63376

Siteman Cancer Center - St Peters, City of Saint Peters

72703

Highlands Oncology Group, Fayetteville

72758

Highlands Oncology Group, Rogers

72762

Highlands Oncology Group, Springdale

80524

UCHealth Poudre Valley Hospital, Fort Collins

80528

UCHealth Harmony, Fort Collins

80538

UCHealth - Medical Center of the Rockies, Loveland

80634

UCHealth Greeley Hospital, Greeley

94304

Stanford Cancer Center, Palo Alto

Stanford Cancer Institute - Clinical Trials Office, Palo Alto

00168

Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore, Roma